ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 157 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $709 | -16.9% | 17,526 | -4.4% | 0.01% | -16.7% |
Q4 2022 | $853 | -99.9% | 18,338 | -5.5% | 0.01% | -25.0% |
Q3 2022 | $1,006,000 | +9.7% | 19,400 | 0.0% | 0.01% | +14.3% |
Q2 2022 | $917,000 | -33.6% | 19,400 | 0.0% | 0.01% | -12.5% |
Q1 2022 | $1,381,000 | +31.0% | 19,400 | +37.2% | 0.01% | +60.0% |
Q4 2021 | $1,054,000 | +123.3% | 14,141 | +50.4% | 0.01% | +25.0% |
Q2 2020 | $472,000 | -85.3% | 9,400 | -85.0% | 0.00% | -76.5% |
Q1 2020 | $3,220,000 | +57.0% | 62,600 | +88.6% | 0.02% | +6.2% |
Q4 2019 | $2,051,000 | +18.1% | 33,200 | +14.9% | 0.02% | +6.7% |
Q3 2019 | $1,736,000 | -14.3% | 28,900 | +20.4% | 0.02% | -11.8% |
Q2 2019 | $2,025,000 | -29.1% | 24,000 | -19.7% | 0.02% | -34.6% |
Q1 2019 | $2,856,000 | +16.9% | 29,900 | -13.3% | 0.03% | +18.2% |
Q4 2018 | $2,444,000 | +63.3% | 34,500 | -49.2% | 0.02% | +29.4% |
Q2 2016 | $1,497,000 | -67.4% | 67,900 | -56.6% | 0.02% | -67.3% |
Q1 2016 | $4,593,000 | -28.6% | 156,400 | -18.8% | 0.05% | -37.3% |
Q4 2015 | $6,437,000 | – | 192,500 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 1,599,109 | $63,277,000 | 8.68% |
SENZAR ASSET MANAGEMENT, LLC | 566,903 | $22,432,000 | 6.58% |
Sarissa Capital Management LP | 105,000 | $4,155,000 | 1.60% |
INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 136,637 | $5,407,000 | 1.41% |
RA Capital Management | 250,000 | $9,893,000 | 1.17% |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 110,515 | $4,373,000 | 0.99% |
Ghost Tree Capital, LLC | 35,000 | $1,385,000 | 0.75% |
WALL STREET ASSOCIATES | 159,100 | $6,296,000 | 0.65% |
BAILARD, INC. | 91,500 | $3,621,000 | 0.56% |
EAM Investors, LLC | 62,768 | $2,484,000 | 0.50% |